StemCells inks pact with Stem Cell Therapeutics

StemCells has struck a licensing deal with Canada's Stem Cell Therapeutics. Stem Cell Therapeutics will pay StemCells an unspecified upfront payment and milestone fees for neural stem cell technology. StemCells in turn will get access to Stem Cell Therapeutics' IP portfolio to develop new drugs and tests. StemCells is developing therapies using adult stem cells.

- here's the AP report on the stem cell pact

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.